Par's generic carisoprodol/aspirin
Firm received approval for the combination tablet formulation March 31. Carter-Wallace markets the muscle relaxant under the brand name Soma Compound, with estimated sales at $10 mil., Par said in an April 5 release. FDA had approved Par's ANDA June 7, 1988, but subsequently rescinded approval because of possible infringement on Carter-Wallace's formulation patent scheduled to expire 2002. Par has since certified that its generic does not infringe on the patent. Par is the second generic company to receive an ANDA approval for the combination product, following Bolar's approval in 1985.
You may also be interested in...
The final opinion of ECHA’s Socio-Economic Analysis Committee, published on 1 March, is largely unchanged from its July 2020 draft opinion with regard to microplastic in cosmetic products. That means industry may have to convince EU member state authorities that the restriction proposal has a serious proportionality problem.
Representatives from cardiac monitoring device manufacturers and professional societies are working together to persuade Medicare carrier Novitas to reconsider its payment rates for extended cardiac monitoring. See what Michael Coyle, iRhythm’s CEO, said about it here.
As agency implements testing contract for its staff, sponsors are drawing up protocols to ensure inspector safety and forwarding them to FDA, but still can’t trigger an inspection.